Topics

Latest "Affordable Sickle Cell Disease Gene Therapies" News Stories

07:19 EST 19th February 2020 | BioPortfolio

Here are the most relevant search results for "Affordable Sickle Cell Disease Gene Therapies" found in our extensive news archives from over 250 global news sources.

More Information about Affordable Sickle Cell Disease Gene Therapies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Affordable Sickle Cell Disease Gene Therapies for you to read. Along with our medical data and news we also list Affordable Sickle Cell Disease Gene Therapies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Affordable Sickle Cell Disease Gene Therapies Companies for you to search.

Showing "Affordable Sickle Cell Disease Gene Therapies" News Articles 1–25 of 29,000+

Wednesday 19th February 2020

Neutralizing Antibodies Against Enteroviruses in HFM Disease

A better understanding of neutralizing antibody responses in hand foot and mouth disease could have important implications for vaccine development. Emerging Infectious Diseases


Tmunity to Present at Upcoming Investor Conferences

Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, today announced that management is scheduled to present at two upcoming investor conferences. Cowen 40th Annual Health Care Conference Monday, March 2, 2020 1:30 PM ET Boston, MA Oppenheimer 30th Annual Hea...

20s Proteasome Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

20s Proteasome Pipeline Review, H2 2019Summary20s Proteasome 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four...


Aroa Biosurgery Expands Options for Soft Tissue Repair with Launch of Myriad™

Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has launched Myriad™, a new product for soft tissue repair and reconstruction, in the United States market. Aroa Chief Executive, Brian Ward says the product name, Myriad™, reflects the multitude of potential uses for this product in soft tissue repair and reconstruction. “As the name implies, our latest ECM ...

Covid-19: a puzzle with many missing pieces

By 15 February 2020, 51 800 cases of the novel coronavirus disease (formerly known as 2019-nCoV and renamed covid-19), including more than 1600 deaths, had been confirmed in China, mainly in Hubei...

BIA Separations and University of Zagreb Sign License Agreement to Commercialize Novel Elution Method for Virus and Viral Vector purification.

Agreement gives BIA Separations access to proprietary technology to better preserve integrity, infectivity and potency of immunoaffinity-purified viral vectors for gene therapy Ajdovšcina, Slovenia and Zagreb, Croatia, 19 February 2020: BIA Separations, a leading bio-chromatography development and manufacturing company, announced it has signed a licensing agreement with the University o...

Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH

-Phase 1 study demonstrated TERN-101 is safe and exhibits potent target engagement at all dose levels studied- -Phase 2 studies of TERN-101 expected to begin in NASH patients in mid-2020- Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced the complet...

Keratoconus Pipeline Review2019 [Published by First View Insight] Prices from USD $1063

Firstview Insight's Keratoconus Pipeline Review2019 provides an overview of the pipeline landscape of Keratoconus It provides comprehensive insights of all the clinical and nonclinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing competito...

[Correspondence] Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19

We are public health scientists who have closely followed the emergence of 2019 novel coronavirus disease (COVID-19) and are deeply concerned about its impact on global health and wellbeing. We have watched as the scientists, public health professionals, and medical professionals of China, in particular, have worked diligently and effectively to rapidly identify the pathogen behind this outbreak, ...

[Correspondence] A distinct name is needed for the new coronavirus

An outbreak of unusual respiratory disease, initially dominated by pneumonia, in Wuhan, China, is caused by infection by a novel coronavirus. The new virus was initially named 2019-nCoV by WHO.1–3

CANbridge Closes $98 Million D Round for Rare Disease/Oncology Portfolio

CANbridge Pharma, a Beijing biopharma developing products for orphan diseases and targeted cancers, closed a $98 million Series D financing led by General Atlantic and WuXi AppTec. Each of the two companies has the option to invest up to an additional $10 million. CANbridge has a global partnership with WuXi Biologics to develop novel therapeutics that treat rare genetic diseases. In January, CANb...

SkinBioTherapeutics signs agreement with Winclove Probiotics to develop psoriasis food supplement.

Commencement of new strategic pillar for SkinBioTherapeutics, targeting the gut-skin axis Second deal signed, demonstrating continued focus and delivery on commercial strategy Manchester, UK – 19 February 2020 – SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”), a life science company focused on skin health, announces...

New ME Association Leaflet: Is ME a neurological disease? | 19 February 2020

We summarise all the key clinical, research and political evidence supporting a neurological classification for M.E. The post New ME Association Leaflet: Is ME a neurological disease? | 19 February 2020 appeared first on ME Association.

Audentes Therapeutics to build gene therapy manufacturing facility in North Carolina

The company will invest around $109m to develop the 135,000ft² gene therapy manufacturing facility. North Carolina Governor Roy Cooper said: “With our powerhouse research centres and highly-skilled workforce, The post Audentes Therapeutics to build gene therapy manufacturing facility in North Carolina appeared first on Pharmaceutical Business review.

Catalent Announces Launch of Private Offering of €450 Million of Senior Unsecured Notes Due 2028

Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions...

'Eavesdropping' on Cancer Cell Signaling Could Lead to New Treatment Options http://dlvr.it/RQK1wK pic.twitter.com/0QrMxJef1i

'Eavesdropping' on Cancer Cell Signaling Could Lead to New Treatment Options http://dlvr.it/RQK1wK  pic.twitter.com/0QrMxJef1i

Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer

New Chief Medical Officer has a deep expertise in gene therapy and small molecule clinical development across disease areas Appointment accelerates strategic move into gene therapy to potentially restore hearing Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, t...

Genentech Says FDA Grants Priority Review To Tecentriq Monotherapy

Genentech, a member of Swiss drug maker Roche Group (RHHBY) said Wednesday that the U.S. Food and Drug Administration or FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) as a first-line monotherapy for certain people with advanced non-small cell lung cancer.

Community Acquired Pneumonia Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $1700

Community Acquired Pneumonia Pipeline Review, H2 2019SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia Pipeline Review, H2 2019, provides an overview of the Community Acquired Pneumonia Infectious Disease pipeline landscape.Communityacquired pneumonia CAP is defined as pneumonia acquired outside a hospital or longterm care fac...

F. Hoffmann-La Roche Ltd: FDA grants priority review to Roche's Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer

Basel, 19 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sB...

FDA Grants Priority Review to Genentech’s Tecentriq Monotherapy as First-line Treatment of Certain People With Advanced Non-small Cell Lung Cancer

  Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as a first-line (initial) monotherapy for people with advanced non-squamous and squamous non-small cell lung cancer (NSCLC)...

Chinese Scientist Unite Together to Tackle With COVID-19

BEIJING, Feb. 19, 2020 /PRNewswire/ -- Reported by Science & Technology Daily: As to the battle against the COVID-19, Chinese Ministry of Science and Technology (MOST) has been launched the program of "Dealing With the Outbreak of COVID-19 Using Science and Technology", a program including four batches of 20 emergency projects until now. Moreover, MOST re-examining two maj...

Tuesday 18th February 2020

20172025 World Eyesight Test Device Market Research Report by Product Type, EndUser / Application and Regions / Countries [Published by HeyReport] Prices from USD $2380

SummaryEyesight test device is a kind of equipment which can offer related eye test to check the structures of the eye for evidence of eye disease or eye problems, such as farsightedness, nearsightedness, misshaped eye, pupillary distance and so on.This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; a...

20172025 World Hydrogen Fuel Cells Market Research Report by Product Type, EndUser / Application and Regions / Countries [Published by HeyReport] Prices from USD $2380

SummaryHydrogen fuel cells use hydrogen as a chemical element, and are made into batteries that store energy. The basic principle is the reverse reaction of electrolysis of water, hydrogen and oxygen were supplied to the cathode and anode, hydrogen diffusion through the cathode and the electrolyte reaction, the release of electrons through the external load to reach the anode.A hydrogen fuel cell ...

Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck’s supplemental Biologics License Applications (sBLAs) seeking to update the dosing frequency for KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, to include a 400 mg dose infused over 30 minutes every-s...


Quick Search

News Quicklinks